Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	extracellular matrix constituent, lubricant activity	MUC17 MUC3A	5.13e-05	4	59	2	GO:0030197
GeneOntologyCellularComponent	ankyrin-1 complex	GYPA GYPB GYPE	2.94e-06	10	62	3	GO:0170014
GeneOntologyCellularComponent	Golgi lumen	MUC17 MUC16 PPIL2 MUC3A MUC6	1.80e-05	109	62	5	GO:0005796
Domain	Glycophorin	GYPA GYPB GYPE	1.26e-07	4	60	3	IPR001195
Domain	GLYCOPHORIN_A	GYPA GYPB	1.01e-05	2	60	2	PS00312
Domain	Glycophorin_CS	GYPA GYPB	1.01e-05	2	60	2	IPR018938
Domain	SEA	MUC17 MUC16 MUC3A	1.12e-05	14	60	3	SM00200
Domain	SEA	MUC17 MUC16 MUC3A	5.33e-05	23	60	3	PS50024
Domain	SEA_dom	MUC17 MUC16 MUC3A	5.33e-05	23	60	3	IPR000082
Domain	APC_su10/DOC_dom	MYCBP2 HERC2	2.11e-04	7	60	2	IPR004939
Domain	DOC	MYCBP2 HERC2	2.11e-04	7	60	2	PS51284
Domain	U_BOX	PPIL2 UBOX5	2.11e-04	7	60	2	PS51698
Domain	APC10	MYCBP2 HERC2	2.11e-04	7	60	2	SM01337
Domain	ANAPC10	MYCBP2 HERC2	2.11e-04	7	60	2	PF03256
Domain	Ubox	PPIL2 UBOX5	2.81e-04	8	60	2	SM00504
Domain	Cyt_P450_E_grp-IV	CYP26B1 CYP4F12	4.49e-04	10	60	2	IPR002403
Domain	Ubox_domain	PPIL2 UBOX5	4.49e-04	10	60	2	IPR003613
Domain	-	MUC17 MUC16	1.04e-03	15	60	2	3.30.70.960
Domain	RCC1	MYCBP2 HERC2	1.86e-03	20	60	2	PF00415
Domain	RCC1_1	MYCBP2 HERC2	2.05e-03	21	60	2	PS00625
Domain	RCC1_2	MYCBP2 HERC2	2.05e-03	21	60	2	PS00626
Domain	RCC1_3	MYCBP2 HERC2	2.05e-03	21	60	2	PS50012
Domain	Reg_chr_condens	MYCBP2 HERC2	2.25e-03	22	60	2	IPR000408
Domain	-	MYCBP2 HERC2	2.25e-03	22	60	2	2.130.10.30
Domain	SEA	MUC17 MUC16	2.25e-03	22	60	2	PF01390
Domain	RCC1/BLIP-II	MYCBP2 HERC2	2.46e-03	23	60	2	IPR009091
Domain	-	MYCBP2 PCLO SYTL2 PPIL2 UBOX5 RNF157	3.12e-03	449	60	6	3.30.40.10
Domain	Galactose-bd-like	MYCBP2 HERC2 UBOX5	3.43e-03	94	60	3	IPR008979
Domain	Znf_RING/FYVE/PHD	MYCBP2 PCLO SYTL2 PPIL2 UBOX5 RNF157	3.48e-03	459	60	6	IPR013083
Domain	Ig_E-set	A2M MYCBP2 REL	4.56e-03	104	60	3	IPR014756
Domain	p53-like_TF_DNA-bd	REL RUNX3	1.26e-02	53	60	2	IPR008967
Domain	Cyt_P450_CS	CYP26B1 CYP4F12	1.26e-02	53	60	2	IPR017972
Domain	PDZ	WHRN RHPN2 PCLO	1.27e-02	151	60	3	PS50106
Pathway	REACTOME_DEFECTIVE_GALNT3_CAUSES_HFTC	MUC17 MUC16 MUC3A MUC6	1.75e-07	16	46	4	M27410
Pathway	REACTOME_DEFECTIVE_C1GALT1C1_CAUSES_TNPS	MUC17 MUC16 MUC3A MUC6	2.29e-07	17	46	4	M27412
Pathway	REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS	MUC17 MUC16 MUC3A MUC6	8.40e-07	23	46	4	M556
Pathway	REACTOME_DECTIN_2_FAMILY	MUC17 MUC16 MUC3A MUC6	1.41e-06	26	46	4	M27483
Pathway	REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS	MUC17 MUC16 MUC6	4.15e-05	21	46	3	MM15706
Pathway	REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS	MUC17 MUC16 MUC3A MUC6	4.82e-05	62	46	4	M546
Pathway	REACTOME_DISEASES_ASSOCIATED_WITH_O_GLYCOSYLATION_OF_PROTEINS	MUC17 MUC16 MUC3A MUC6	6.94e-05	68	46	4	M27303
Pathway	REACTOME_C_TYPE_LECTIN_RECEPTORS_CLRS	MUC17 MUC16 MAP3K7 MUC3A MUC6	8.89e-05	140	46	5	M27484
Pathway	REACTOME_RUNX3_REGULATES_YAP1_MEDIATED_TRANSCRIPTION	TEAD3 RUNX3	1.55e-04	6	46	2	MM15544
Pathway	REACTOME_RUNX3_REGULATES_YAP1_MEDIATED_TRANSCRIPTION	TEAD3 RUNX3	2.88e-04	8	46	2	M27823
Pathway	REACTOME_O_LINKED_GLYCOSYLATION	MUC17 MUC16 MUC3A MUC6	4.61e-04	111	46	4	M27416
Pubmed	Novel hybrid genes and a splice site mutation encoding the Sta antigen among Japanese blood donors.	GYPA GYPB GYPE	5.39e-09	3	62	3	32394466
Pubmed	Isolation and pathogenic characterization of an OB1 variant of Babesia rodhaini which has a glycophorin A-independent pathway to murine red blood cells.	GYPA GYPB GYPE	5.39e-09	3	62	3	19084340
Pubmed	Characterization of glycophorin A transcripts: control by the common erythroid-specific promoter and alternative usage of different polyadenylation signals.	GYPA GYPB GYPE	5.39e-09	3	62	3	7798177
Pubmed	Full length mouse glycophorin gene constructed using recombinant polymerase chain reaction.	GYPA GYPB GYPE	5.39e-09	3	62	3	2043106
Pubmed	Rapidly evolving genes in human. I. The glycophorins and their possible role in evading malaria parasites.	GYPA GYPB GYPE	5.39e-09	3	62	3	12949139
Pubmed	Detailed physical mapping of the genes encoding glycophorins A, B and E, as revealed by P1 plasmids containing human genomic DNA.	GYPA GYPB GYPE	5.39e-09	3	62	3	7622054
Pubmed	Regulatory function of delta/YY-1 on the locus control region-like sequence of mouse glycophorin gene in erythroleukemia cells.	GYPA GYPB GYPE	5.39e-09	3	62	3	8662744
Pubmed	Isolation of the cDNA clone for mouse glycophorin, erythroid-specific membrane protein.	GYPA GYPB GYPE	5.39e-09	3	62	3	2753361
Pubmed	Structural variation of the malaria-associated human glycophorin A-B-E region.	GYPA GYPB GYPE	5.39e-09	3	62	3	32600246
Pubmed	Mechanism of protein sorting during erythroblast enucleation: role of cytoskeletal connectivity.	GYPA GYPB GYPE	5.39e-09	3	62	3	14563645
Pubmed	Glycophorin A requirement for expression of O-linked antigens on the erythrocyte membrane.	GYPA GYPB GYPE	2.16e-08	4	62	3	12940824
Pubmed	SCL assembles a multifactorial complex that determines glycophorin A expression.	GYPA GYPB GYPE	2.16e-08	4	62	3	14749362
Pubmed	Targeted erythropoietin selectively stimulates red blood cell expansion in vivo.	GYPA GYPB GYPE	2.16e-08	4	62	3	27114509
Pubmed	Interactions of mouse glycophorin A with the dRTA-related mutant G719D of the mouse Cl-/HCO3- exchanger Ae1.	GYPA GYPB GYPE	2.16e-08	4	62	3	21455273
Pubmed	Mucin gene expression in human laryngeal epithelia: effect of laryngopharyngeal reflux.	MUC17 MUC16 MUC3A MUC6	2.75e-08	18	62	4	18834073
Pubmed	Direct association of YY-1 with c-Myc and the E-box binding protein in regulation of glycophorin gene expression.	GYPA GYPB GYPE	5.38e-08	5	62	3	9747880
Pubmed	Complete deficiency of glycophorin A in red blood cells from mice with targeted inactivation of the band 3 (AE1) gene.	GYPA GYPB GYPE	5.38e-08	5	62	3	9490702
Pubmed	Genetic control of blood parasitaemia in mouse malaria maps to chromosome 8.	GYPA GYPB GYPE	5.38e-08	5	62	3	9398835
Pubmed	The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage.	GYPA GYPB GYPE	1.07e-07	6	62	3	10848813
Pubmed	Disruption of palladin leads to defects in definitive erythropoiesis by interfering with erythroblastic island formation in mouse fetal liver.	GYPA GYPB GYPE REL	1.13e-07	25	62	4	17431131
Pubmed	Structural organization of the mouse glycophorin A gene.	GYPA GYPB GYPE	1.88e-07	7	62	3	7896738
Pubmed	Genetic mapping near the myd locus on mouse chromosome 8.	GYPA GYPB GYPE	3.00e-07	8	62	3	7613034
Pubmed	Erythroferrone contributes to iron mobilization for embryo erythropoiesis in iron-deficient mouse pregnancies.	GYPA GYPB GYPE	3.00e-07	8	62	3	36071577
Pubmed	EKLF and KLF2 have compensatory roles in embryonic beta-globin gene expression and primitive erythropoiesis.	GYPA GYPB GYPE	6.42e-07	10	62	3	17675555
Pubmed	KLF2 is essential for primitive erythropoiesis and regulates the human and murine embryonic beta-like globin genes in vivo.	GYPA GYPB GYPE	6.42e-07	10	62	3	15947087
Pubmed	The Poly(C) Binding Protein Pcbp2 and Its Retrotransposed Derivative Pcbp1 Are Independently Essential to Mouse Development.	GYPA GYPB GYPE	2.97e-06	16	62	3	26527618
Pubmed	Isolation of cDNA clones for human erythrocyte membrane sialoglycoproteins alpha and delta.	GYPA GYPB	3.13e-06	2	62	2	3196288
Pubmed	Molecular genetics of glycophorin MNS variants.	GYPA GYPB	3.13e-06	2	62	2	9269716
Pubmed	Molecular genetics of human erythrocyte MiIII and MiVI glycophorins. Use of a pseudoexon in construction of two delta-alpha-delta hybrid genes resulting in antigenic diversification.	GYPA GYPB	3.13e-06	2	62	2	2016325
Pubmed	Identification of a novel human glycophorin, glycophorin E, by isolation of genomic clones and complementary DNA clones utilizing polymerase chain reaction.	GYPB GYPE	3.13e-06	2	62	2	2295603
Pubmed	Gene conversion confined to a direct repeat of the acceptor splice site generates allelic diversity at human glycophorin (GYP) locus.	GYPA GYPB	3.13e-06	2	62	2	1737789
Pubmed	Characterization of alternatively spliced transcript variants of glycophorin A and glycophorin B genes in Chinese blood donors.	GYPA GYPB	3.13e-06	2	62	2	35138639
Pubmed	Identification of recombination events resulting in three hybrid genes encoding human MiV, MiV(J.L.), and Sta glycophorins.	GYPA GYPB	3.13e-06	2	62	2	2015404
Pubmed	Glycophorin He(Sta) of the human red blood cell membrane is encoded by a complex hybrid gene resulting from two recombinational events.	GYPA GYPB	3.13e-06	2	62	2	8193374
Pubmed	MNSs blood group glycophorin variants in Taiwan: a genotype-serotype correlation study of 'Mi(a)' and St(a) with report of two new alleles for St(a).	GYPA GYPB	3.13e-06	2	62	2	24858913
Pubmed	Molecular basis for the human erythrocyte glycophorin specifying the Miltenberger class I (MiI) phenotype.	GYPA GYPB	3.13e-06	2	62	2	1611092
Pubmed	Molecular genetics of the glycophorin gene family, the antigens for MNSs blood groups: multiple gene rearrangements and modulation of splice site usage result in extensive diversification.	GYPA GYPB	3.13e-06	2	62	2	8535438
Pubmed	Resistance to malaria through structural variation of red blood cell invasion receptors.	GYPA GYPB	3.13e-06	2	62	2	28522690
Pubmed	The genotypes of GYPA and GYPB carrying the MNSs antigens are not associated with cerebral malaria.	GYPA GYPB	3.13e-06	2	62	2	17372674
Pubmed	Molecular analysis of human glycophorin MiIX gene shows a silent segment transfer and untemplated mutation resulting from gene conversion via sequence repeats.	GYPA GYPE	3.13e-06	2	62	2	1421409
Pubmed	Characterization of GYPMur and novel GYPBun-like hybrids in Thai blood donors reveals a qualitatively altered s antigen.	GYPA GYPB	3.13e-06	2	62	2	32201961
Pubmed	Structural organization of glycophorin A and B genes: glycophorin B gene evolved by homologous recombination at Alu repeat sequences.	GYPA GYPB	3.13e-06	2	62	2	2734312
Pubmed	Molecular cloning of a human glycophorin B cDNA: nucleotide sequence and genomic relationship to glycophorin A.	GYPA GYPB	3.13e-06	2	62	2	3477806
Pubmed	Exon skipping caused by DNA recombination that introduces a defective donor splice site into the human glycophorin A gene.	GYPA GYPB	3.13e-06	2	62	2	8444872
Pubmed	Confirmation and dissection of QTL controlling resistance to malaria in mice.	GYPA GYPB GYPE	3.60e-06	17	62	3	15170228
Pubmed	Kruppel-like factor 1 (KLF1), KLF2, and Myc control a regulatory network essential for embryonic erythropoiesis.	GYPA GYPB GYPE	4.32e-06	18	62	3	22566683
Pubmed	Circulating primitive erythroblasts establish a functional, protein 4.1R-dependent cytoskeletal network prior to enucleating.	GYPA GYPB GYPE	4.32e-06	18	62	3	28701737
Pubmed	Transcription arrest relief by S-II/TFIIS during gene expression in erythroblast differentiation.	GYPA GYPB GYPE	5.12e-06	19	62	3	19210546
Pubmed	Differential Etv2 threshold requirement for endothelial and erythropoietic development.	GYPA GYPB GYPE	8.11e-06	22	62	3	35649376
Pubmed	Genomic organization and structure of the 3' region of human MUC3: alternative splicing predicts membrane-bound and soluble forms of the mucin.	MUC17 MUC3A	9.37e-06	3	62	2	10512748
Pubmed	Reciprocal interaction between SIRT6 and APC/C regulates genomic stability.	POM121 MYCBP2 RBM10 HERC2 MED1 LARP4 ESF1	1.34e-05	440	62	7	34244565
Pubmed	The low affinity p75 neurotrophin receptor is down-regulated in congenital anomalies of the kidney and the urinary tract: Possible involvement in early nephrogenesis.	SLC34A1 EYA1	1.87e-05	4	62	2	32988586
Pubmed	Stress-sensitive neural circuits change the gut microbiome via duodenal glands.	GLP1R CCKAR	1.87e-05	4	62	2	39121857
Pubmed	Screen and identification of proteins interacting with ADAM19 cytoplasmic tail.	COPB1 ESF1	3.12e-05	5	62	2	12463424
Pubmed	Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death.	GSDMD MAP3K7	3.12e-05	5	62	2	30361383
Pubmed	Distinct roles of transforming growth factor-beta-activated kinase 1 (TAK1)-c-Rel and interferon regulatory factor 4 (IRF4) pathways in human T cell lymphotropic virus 1-transformed T helper 17 cells producing interleukin-9.	REL MAP3K7	3.12e-05	5	62	2	21498517
Pubmed	Protein interaction network of alternatively spliced NudCD1 isoforms.	COPB1 RBM10	4.67e-05	6	62	2	29021621
Pubmed	Expression of Muc19/Smgc gene products during murine sublingual gland development: cytodifferentiation and maturation of salivary mucous cells.	MUC16 MUC6	4.67e-05	6	62	2	19110483
Pubmed	Regulator of G protein signaling 12 drives inflammatory arthritis by activating synovial fibroblasts through MYCBP2/KIF2A signaling.	MYCBP2 HERC2	6.53e-05	7	62	2	36700049
Pubmed	ANKRD13a controls early cell-death checkpoint by interacting with RIP1 independent of NF-κB.	GYPA GYPB GYPE	6.78e-05	44	62	3	34839354
Pubmed	ADAMTS3 activity is mandatory for embryonic lymphangiogenesis and regulates placental angiogenesis.	GYPA GYPB GYPE	7.26e-05	45	62	3	26446156
Pubmed	Architecture of the human erythrocyte ankyrin-1 complex.	GYPA GYPB	8.69e-05	8	62	2	35835865
Pubmed	Introduction of a real-time-based blood-group genotyping approach.	GYPA GYPB	8.69e-05	8	62	2	18510579
Pubmed	CLEC16A interacts with retromer and TRIM27, and its loss impairs endosomal trafficking and neurodevelopment.	FCSK AMER1 TTC28 COPB1 MYCBP2 SFXN2 HERC2	1.01e-04	606	62	7	36538041
Pubmed	U box proteins as a new family of ubiquitin-protein ligases.	PPIL2 UBOX5	1.39e-04	10	62	2	11435423
Pubmed	Proximity biotinylation and affinity purification are complementary approaches for the interactome mapping of chromatin-associated protein complexes.	A2M TTC28 MYCBP2 CCDC25 PPIL2 MED1 MAP3K7	1.48e-04	645	62	7	25281560
Pubmed	In-silico designing of a potent analogue against HIV-1 Nef protein and protease by predicting its interaction network with host cell proteins.	PACS1 COPB1	2.04e-04	12	62	2	23559827
Pubmed	MED12 Regulates HSC-Specific Enhancers Independently of Mediator Kinase Activity to Control Hematopoiesis.	ERG MED1	2.41e-04	13	62	2	27570068
Pubmed	Interaction of U-box-type ubiquitin-protein ligases (E3s) with molecular chaperones.	PPIL2 UBOX5	2.41e-04	13	62	2	15189447
Pubmed	The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.	ERG HERC2	2.81e-04	14	62	2	27626314
Pubmed	New interaction partners for Nek4.1 and Nek4.2 isoforms: from the DNA damage response to RNA splicing.	WHRN TTC28 RBM10 HERC2 MAP3K7 OMG	3.06e-04	513	62	6	25798074
Pubmed	Multiple common variants for celiac disease influencing immune gene expression.	REL RUNX3 MAP3K7	3.46e-04	76	62	3	20190752
Pubmed	Tissue distribution, ontogeny, and hormonal regulation of xenobiotic transporters in mouse kidneys.	SLC29A3 SLC34A1	3.69e-04	16	62	2	19679677
Pubmed	Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations.	MYCBP2 PCLO SYTL2 MAP3K7 JPH3	3.90e-04	347	62	5	17114649
Pubmed	Defining the proximal interaction networks of Arf GTPases reveals a mechanism for the regulation of PLD1 and PI4KB.	AMER1 TTC28 COPB1 ARFGEF1 MUC16 MAP3K7 ESF1	4.58e-04	777	62	7	35844135
Pubmed	Genome-wide association study of pre-eclampsia detects novel maternal single nucleotide polymorphisms and copy-number variants in subsets of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study cohort.	MYCBP2 MUC22	5.24e-04	19	62	2	23551011
Pubmed	Ontogeny and Trophic Factor Sensitivity of Gastrointestinal Projecting Vagal Sensory Cell Types.	GLP1R CCKAR	5.24e-04	19	62	2	36973009
Pubmed	Loss of Prdm12 during development, but not in mature nociceptors, causes defects in pain sensation.	TRPA1 RUNX3	5.82e-04	20	62	2	33789102
Pubmed	Scanning the human proteome for calmodulin-binding proteins.	MYCBP2 PPIL2 HERC2	6.05e-04	92	62	3	15840729
Pubmed	A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex.	MYCBP2 RBM10	6.42e-04	21	62	2	24923560
Pubmed	Cell fate specification in the lingual epithelium is controlled by antagonistic activities of Sonic hedgehog and retinoic acid.	KRT15 CYP26B1	7.06e-04	22	62	2	28715412
Pubmed	Genetic disruption of CYP26B1 severely affects development of neural crest derived head structures, but does not compromise hindbrain patterning.	CYP26B1 EYA1	7.72e-04	23	62	2	19235731
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	WHRN KIRREL3 TTC28 RBM10 RNF157	8.02e-04	407	62	5	12693553
Pubmed	Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney.	SLC34A1 EYA1	8.41e-04	24	62	2	17036046
Pubmed	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.	REL MAP3K7	8.41e-04	24	62	2	20448286
Pubmed	Mice lacking the epidermal retinol dehydrogenases SDR16C5 and SDR16C6 display accelerated hair growth and enlarged meibomian glands.	KRT15 CYP26B1	9.14e-04	25	62	2	31562240
Pubmed	Interferon-γ primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway.	GSDMD REL	9.14e-04	25	62	2	35139355
Pubmed	Induction of Gastric Cancer by Successive Oncogenic Activation in the Corpus.	RUNX3 MUC6	9.14e-04	25	62	2	34391772
Pubmed	Identification of targets for calcium signaling through the copine family of proteins. Characterization of a coiled-coil copine-binding motif.	PITPNM2 MYCBP2	9.14e-04	25	62	2	12522145
Pubmed	Structure--function relationships in HIV-1 Nef.	PACS1 COPB1	1.07e-03	27	62	2	11463741
Pubmed	Identification by proximity labeling of novel lipidic and proteinaceous potential partners of the dopamine transporter.	NFASC HERC2	1.07e-03	27	62	2	34709416
Pubmed	Genome-wide association study of bipolar disorder accounting for effect of body mass index identifies a new risk allele in TCF7L2.	GYPA JPH3	1.15e-03	28	62	2	24322204
Pubmed	Prox2 and Runx3 vagal sensory neurons regulate esophageal motility.	GLP1R RUNX3	1.23e-03	29	62	2	37192624
Pubmed	Axial skeleton anterior-posterior patterning is regulated through feedback regulation between Meis transcription factors and retinoic acid.	CYP26B1 EYA1	1.23e-03	29	62	2	33298461
Pubmed	USP7 represses lineage differentiation genes in mouse embryonic stem cells by both catalytic and noncatalytic activities.	MAGEB4 AMER1 TRPA1 GYPA GYPB GYPE	1.27e-03	674	62	6	37196079
Pubmed	TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis.	MAP3K7 ESF1	1.32e-03	30	62	2	23973329
Pubmed	Insights into the ubiquitin-proteasome system of human embryonic stem cells.	A2M HERC2 MED1 LARP4	1.37e-03	269	62	4	29511261
Pubmed	New roles for the de-ubiquitylating enzyme OTUD4 in an RNA-protein network and RNA granules.	PACS1 MYCBP2 RBM10 PCLO SFXN2	1.41e-03	462	62	5	31138677
Pubmed	Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers.	AMER1 COPB1 OR2T1 PPIL2 TEAD3 MED1 MAP3K7 ESF1	1.62e-03	1247	62	8	27684187
Pubmed	Mapping the Ku Interactome Using Proximity-Dependent Biotin Identification in Human Cells.	RBM10 PPIL2 MED1 ESF1	1.65e-03	283	62	4	30585729
Cytoband	2p13-p12	REL MXD1	1.07e-05	4	62	2	2p13-p12
Cytoband	8q13	TRPA1 ARFGEF1	1.17e-04	12	62	2	8q13
Cytoband	4q31.21	GYPA GYPB	5.71e-04	26	62	2	4q31.21
Cytoband	6p21.2	NUDT3 TEAD3	1.10e-03	36	62	2	6p21.2
Cytoband	Ensembl 112 genes in cytogenetic band chr4q31	GYPA GYPB GYPE	1.45e-03	164	62	3	chr4q31
Cytoband	Ensembl 112 genes in cytogenetic band chr8q13	ARFGEF1 EYA1	4.80e-03	76	62	2	chr8q13
Cytoband	Ensembl 112 genes in cytogenetic band chr6p21	NUDT3 GLP1R TEAD3 MUC22	4.81e-03	503	62	4	chr6p21
GeneFamily	CD molecules\|Mucins	MUC17 MUC16 MUC22 MUC3A MUC6	2.33e-09	21	49	5	648
GeneFamily	Glycosyltransferase family 6\|Blood group antigens	GYPA GYPB GYPE	1.36e-04	37	49	3	454
GeneFamily	U-box domain containing	PPIL2 UBOX5	1.50e-04	7	49	2	365
ToppCell	PBMC-Control-Hematopoietic-Platelet-Platelet-plt_5\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	KRT15 SLC34A1 MUC16 NFASC MUC22	1.32e-06	136	62	5	27a41463e6f16deb5b1d4f17fefded9959038c07
ToppCell	PBMC-Control-Hematopoietic-Platelet-Platelet-plt_5\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	KRT15 SLC34A1 MUC16 NFASC MUC22	1.32e-06	136	62	5	88b5c839d0446c6d6b7e81fc4d48f5e7e96eea11
ToppCell	Control-Epithelial_cells-Airway_mucous\|Control / group, cell type (main and fine annotations)	RHPN2 MUC17 MUC16 MUC3A MXD1	5.65e-06	183	62	5	15d24a4fb1ffe6cbafbd54fcd7dde9ddcfbe03b2
ToppCell	10x3'2.3-week_17-19-Endothelial-stroma-proliferating_EC\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	A2M CYP26B1 CCM2L TTC28 RNF157	6.12e-06	186	62	5	a844d4f79e0ad5d6c60a4488ffd8f4f21b7eed04
ToppCell	Children_(3_yrs)-Endothelial-capillary_endothelial_cell_(Cap1)-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	A2M PITPNM2 ERG CCM2L TTC28	6.44e-06	188	62	5	117dc80fa940e6aa1b0187a43fdde33f3fcb578f
ToppCell	COPD-Lymphoid-T_Cytotoxic\|Lymphoid / Disease state, Lineage and Cell class	A2M WHRN SYTL2 CRYBG1 RUNX3	6.78e-06	190	62	5	10bece40d980d37a01dae8ce887655bf9f93040c
ToppCell	PCW_05-06-Endothelial-Endothelial_cycling-endo_proliferating1_(10)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	A2M PITPNM2 CYP26B1 ERG CCM2L	6.78e-06	190	62	5	9a2244c3973aee7270646bf00db7727edb9decc5
ToppCell	Control-Lymphoid-T_Cytotoxic\|Lymphoid / Disease state, Lineage and Cell class	A2M WHRN SYTL2 CRYBG1 RUNX3	6.96e-06	191	62	5	ff7204f9b645233548cf804cf6fe0c86417be87f
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	A2M TTC28 SYTL2 EYA1 RUNX3	7.14e-06	192	62	5	97c312c82ec025c13052f8d424b11c0034c8ea54
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c07-TYROBP\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	A2M TTC28 SYTL2 EYA1 RUNX3	7.14e-06	192	62	5	3b0a52e4e77ae4539a034dcb419773b8e2aa5d51
ToppCell	Children_(3_yrs)-Endothelial-capillary_endothelial_cell_(Cap1)\|Children_(3_yrs) / Lineage, Cell type, age group and donor	A2M PITPNM2 ERG CCM2L TTC28	7.50e-06	194	62	5	71ac69cdf7a08ca3ddfb5b492b14ac56b6cd5e5d
ToppCell	PCW_05-06-Endothelial-Endothelial_cycling\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	A2M PITPNM2 CYP26B1 ERG CCM2L	7.50e-06	194	62	5	eb279e0d922de921343f0ae032a809f837d915b3
ToppCell	PCW_10-12-Endothelial-Endothelial_mature-endo_capillary_(2)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	PITPNM2 KIRREL3 CYP26B1 ERG CCM2L	7.89e-06	196	62	5	2a2a93b89dcb98043cb1f8b422ac8c55e2edc37b
ToppCell	PCW_13-14-Endothelial-Endothelial_cycling-endo_proliferating1_(10)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	PITPNM2 CYP26B1 ERG CCM2L CRYBG1	7.89e-06	196	62	5	b826dce5b3daa8eb3d4a530b9564de58d9ce3767
ToppCell	distal-Endothelial-Artery-3\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	A2M CYP26B1 ERG CCM2L TTC28	8.49e-06	199	62	5	8acf381087268fcf13f025e3b67e028bf1f9b77e
ToppCell	Parenchyma_COVID-19-Endothelial-TX-Artery\|Parenchyma_COVID-19 / Sample group, Lineage and Cell type	A2M CYP26B1 ERG CCM2L TTC28	8.70e-06	200	62	5	34b279804475ea58fbb052b96f44128c082627a9
ToppCell	Lung_Parenchyma-Severe-Endothelial-Endothelial-Artery\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	A2M CYP26B1 ERG CCM2L TTC28	8.70e-06	200	62	5	8552cc7a439449b30b59760c3e8667217b9852b5
ToppCell	Tracheal\|World / Cell types per location group and 10X technology with lineage, and cell group designations	PACS1 KRT15 RHPN2 MUC16 EYA1	8.70e-06	200	62	5	682960e28542a3d6c119047cd0131941932cfdea
ToppCell	Lung_Parenchyma-Severe-Endothelial-Endothelial-Artery-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	A2M CYP26B1 ERG CCM2L TTC28	8.70e-06	200	62	5	45c08f1befe78553bbadcc2fcffb6138306638f3
ToppCell	Globus_pallidus-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Cyp26b1_(Globus_Pallidus_Externus_(GP),_"Arkypallidal")-\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	CYP26B1 MUC17 CCKAR	4.39e-05	49	62	3	389ad8def664f873ca0864df11e2b1dadd8eb9d0
ToppCell	Globus_pallidus-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Cyp26b1_(Globus_Pallidus_Externus_(GP),_"Arkypallidal")--\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	CYP26B1 MUC17 CCKAR	4.39e-05	49	62	3	8ec64217878b0cc289c8078c22729695ab5f5fa5
ToppCell	Globus_pallidus-Neuronal-Inhibitory-iN1(Gad1Gad2_Th)-Inhibitory_Neuron.Gad1Gad2.Cyp26b1_(Globus_Pallidus_Externus_(GP),_"Arkypallidal")\|Globus_pallidus / BrainAtlas - Mouse McCarroll V32	CYP26B1 MUC17 CCKAR	4.39e-05	49	62	3	8d2ed325530dba342223d82e8b08251d782fd6b2
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c09-SLC4A10\|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)	A2M WHRN SAMSN1 RUNX3	5.27e-05	147	62	4	9566398275cad79223db90ffe640830acf2db864
ToppCell	368C-Lymphocytic-NK_cells\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	CYP26B1 GYPB GYPE PCLO	5.70e-05	150	62	4	17b3ac5ddc47b9cba0a27b268d63a6e491b2b111
ToppCell	Healthy_donor-RBC\|World / disease group, cell group and cell class (v2)	A2M KIRREL3 GYPA GYPB	5.70e-05	150	62	4	1e1a497ec4b048f7e9cc12dd5dd9aba7fedca9e1
ToppCell	367C-Lymphocytic-ILC-ILC-2\|ILC / Donor, Lineage, Cell class and subclass (all cells)	A2M WHRN SYTL2	6.21e-05	55	62	3	7916216b3a24f9c6b966aa5392fc2bc43b3d2c4c
ToppCell	Healthy_donor-RBC\|Healthy_donor / disease group, cell group and cell class (v2)	A2M KIRREL3 GYPA GYPB	6.31e-05	154	62	4	e080d5104fe6f3f6ef617bbcdccf1332ab7231e1
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d14-21-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c09-SLC4A10\|Severe-critical_convalescent_d14-21 / Compartment, severity and other cell annotations on 10x 3' data (130k)	A2M KIRREL3 SYTL2 TEAD3	6.31e-05	154	62	4	e94cd11488003347120eacd3ced0a8923ed09ccc
ToppCell	PND07-Immune-Immune_Myeloid-DC-maDC\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	NFASC REL SAMSN1 MXD1	7.32e-05	160	62	4	7db30647b596f0c419087e6fabb9b99dcd5bddd4
ToppCell	PND07-Immune-Immune_Myeloid-DC-maDC-maDC_mature\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	NFASC REL SAMSN1 MXD1	7.32e-05	160	62	4	01f22cdb2a2f73776b7f91746e95c1850df94235
ToppCell	11.5-Airway-RBC-RBC\|Airway / Age, Tissue, Lineage and Cell class	GYPA GYPB GYPE SAMSN1	8.24e-05	165	62	4	8618b2c5659aa70c7c9d6e51a227ac612b4ad17b
ToppCell	11.5-Airway-RBC\|Airway / Age, Tissue, Lineage and Cell class	GYPA GYPB GYPE SAMSN1	8.24e-05	165	62	4	46042340a373adaf1c439b2301e02fbae3e31a4f
ToppCell	normal_Lung-Myeloid_cells-CD163+CD14+_DCs\|Myeloid_cells / Location, Cell class and cell subclass	A2M REL RUNX3 MXD1	8.44e-05	166	62	4	07b498eb341abec02a3ccaae320bdbb5cd6883c5
ToppCell	PND10-Immune-Immune_Myeloid-DC-maDC-maDC_mature\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	GSDMD REL SAMSN1 MXD1	9.04e-05	169	62	4	a83e4078db91ecedee637b28b12ec38640fe45f9
ToppCell	tumor_Lymph_Node_/_Brain-B_lymphocytes-Plasma_cells\|B_lymphocytes / Location, Cell class and cell subclass	SLC29A3 KRT15 MUC16 OMG	9.04e-05	169	62	4	150c08c7b1dc0f46173a7b8f6a3fc70d82906c0d
ToppCell	PND10-Immune-Immune_Myeloid-DC-maDC\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	GSDMD REL SAMSN1 MXD1	9.04e-05	169	62	4	f914aa8899fa170a09da31e5fad86de897ea789b
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-hematologic-hematopoietic_progenitor-erythroid_progenitor_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	GYPA GYPB GYPE MUC6	9.25e-05	170	62	4	74bb46826141bd1e80b4ce16e6bbfc770bd427d3
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-hematologic-hematopoietic_progenitor\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	GYPA GYPB GYPE MUC6	9.25e-05	170	62	4	6592ebe204b43b81c6b6da99e05da72c0983b3fa
ToppCell	facs\|World / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KRT15 NUDT3 ERG MED1	9.46e-05	171	62	4	c9990bc041a632b2f7bbebbfe737772c423d7027
ToppCell	COVID-19-Heart-T_cell\|COVID-19 / Disease (COVID-19 only), tissue and cell type	KIRREL3 GYPA GYPB RUNX3	9.46e-05	171	62	4	b2e753e811a7639956994609f73efcdb62d04f82
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Immune-Myeloid-Monocytic-Monocyte-derived_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MUC16 SAMSN1 RUNX3 MXD1	9.68e-05	172	62	4	72fbfa890995e47048b47199c170cc7dcd7661f8
ToppCell	renal_papilla_nuclei-Hypertensive_with+without-CKD-Immune-Myeloid-Monocytic\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	MUC16 SAMSN1 RUNX3 MXD1	9.68e-05	172	62	4	2ca6f0d1181aabe0d0e3e8f2e193f08dbda42dea
ToppCell	facs-Lung-18m-Hematologic-myeloid-myeloid_dendritic_cell-Ccr7+_dendritic\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TRPA1 REL SAMSN1 MXD1	9.68e-05	172	62	4	48d0cfc37d1b1ae48ed8f8b2711abeb609d2bb6e
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c05-ZNF683\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	A2M TRPA1 SYTL2 RUNX3	1.06e-04	176	62	4	5914e7635474e7cf24d446bdb1423bc0807ee9c6
ToppCell	wk_20-22-Hematologic-Meg-ery-Cycling_definitive_erythroblast\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	DUSP21 GYPA GYPB GYPE	1.06e-04	176	62	4	98814f0a67411b2f7b25dc489b2aadb77f45a853
ToppCell	wk_15-18-Hematologic-Meg-ery-Primitive_erythrocyte\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	DUSP21 GYPA GYPB GYPE	1.06e-04	176	62	4	664a7d15563428d0ae156d97aa88415fd0a0506a
ToppCell	droplet-Kidney-nan-18m-Lymphocytic\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	REL SAMSN1 RUNX3 MXD1	1.13e-04	179	62	4	58be9ab455875035978c78ba7d7e4b3c9f3dc4e5
ToppCell	5'-GW_trimst-2-LymphNode-Hematopoietic-Red_blood_cells\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	DUSP21 GYPA GYPB GYPE	1.18e-04	181	62	4	577bf37a6594fad01251d2c66d8ccda8e949b6cf
ToppCell	5'-GW_trimst-2-LymphNode-Hematopoietic-Red_blood_cells-RBC\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	DUSP21 GYPA GYPB GYPE	1.18e-04	181	62	4	f5dc7a650afe8837cb424981e50ad2c8b18c7c32
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Hematopoietic\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	ERG GYPA GYPB GYPE	1.18e-04	181	62	4	9dc0563453e24c9d1d975e2e0e1e272487e19908
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Hematopoietic-Megakaryocytic\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	ERG GYPA GYPB GYPE	1.18e-04	181	62	4	14c2dd946e89ba578711c2d25935b6b3d319b701
ToppCell	3'-GW_trimst-1-SmallIntestine-Hematopoietic-Red_blood_cells-RBC\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	DUSP21 GYPA GYPB GYPE	1.18e-04	181	62	4	f4cd6dba4c04c5cb550f44468eb29c07238fbda4
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Hematopoietic-Megakaryocytic-Megakaryocyte\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	ERG GYPA GYPB GYPE	1.18e-04	181	62	4	c5843b89f3d362e236ff76c3279518a2fdfc1f75
ToppCell	3'-GW_trimst-1-SmallIntestine-Hematopoietic-Red_blood_cells\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	DUSP21 GYPA GYPB GYPE	1.18e-04	181	62	4	c7f5d0e5aa2ca6a409957713637e1b37a73ceb60
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Hematopoietic-Megakaryocytic-Megakaryocyte-Mega\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	ERG GYPA GYPB GYPE	1.18e-04	181	62	4	fcefb5902416c004631f4f8dd5c8f99fe3bd90bc
ToppCell	10x_3'_v3-spleen_(10x_3'_v3)-hematologic\|spleen_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	ERG GYPA GYPB GYPE	1.23e-04	183	62	4	1db466cf757813322db1cdcc0bf1d91c062fd9de
ToppCell	Healthy_Control-Lymphoid-NK\|Healthy_Control / Condition, Lineage, Cell class and cell subclass	TRPA1 SLC34A1 SYTL2 RUNX3	1.23e-04	183	62	4	b41b1f32022c8632a638cf1c5523c9a24176f568
ToppCell	droplet-Fat-BAT+GAT+MAT-30m-Lymphocytic-lymphocyte\|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	WHRN REL RUNX3 JPH3	1.23e-04	183	62	4	a305667cfdae50e64e1890f10f71b407ae617b80
ToppCell	5'-GW_trimst-1-SmallIntestine-Endothelial-blood_vessel_EC-venous_capillary\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M PITPNM2 CYP26B1 SAMSN1	1.25e-04	184	62	4	97e97de52daaff8840f4ee76a94ba5e3f79de7ce
ToppCell	wk_15-18-Hematologic-Meg-ery-Cycling_definitive_erythroblast\|wk_15-18 / Celltypes from embryonic and fetal-stage human lung	DUSP21 GYPA GYPB GYPE	1.25e-04	184	62	4	238eba615b4e04967d44ac7858a6673bdd7f67e9
ToppCell	Healthy/Control-CD4+_CTL\|Healthy/Control / Disease group and Cell class	WHRN TRPA1 SAMSN1 JPH3	1.25e-04	184	62	4	6c6ffa150f81e456f88e9065de90c2dcda417589
ToppCell	10x5'v1-week_17-19-Hematopoietic-erythroid-mid_erythroid\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	GYPA GYPB GYPE CYP4F12	1.28e-04	185	62	4	e9059cefcdf0972ec90793b1dd34c3292b17a061
ToppCell	ILEUM-inflamed-(7)_Lymphatics\|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	ERG PCLO EYA1 OMG	1.28e-04	185	62	4	d711dd2e91cfee723dae1ccb2b910b8cf3becc3b
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c08-IL2RB\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	TTC28 SYTL2 EYA1 RUNX3	1.31e-04	186	62	4	facc1bd8920003ad03d1893c32fc606d82b4d50a
ToppCell	(5)_Epithelial_cells-(5)_Glands_duct\|(5)_Epithelial_cells / Oesophagus cell shreds on cell class (v1) and cell subclass (v1)	KIRREL3 SYTL2 MUC16 RUNX3	1.31e-04	186	62	4	219b1aeca17503244fabbb780bca58f22c7c0f27
ToppCell	3'-GW_trimst-1-SmallIntestine-Endothelial-blood_vessel_EC-arterial_capillary\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M CYP26B1 ERG CCM2L	1.34e-04	187	62	4	50d5730e2cd4951d3ad0641fc81ae9f6ddabafe7
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c05-ZNF683\|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k)	A2M TTC28 SYTL2 EYA1	1.34e-04	187	62	4	cfdc1585c80d2bb475d9145395fb50a88c53f838
ToppCell	Endothelial-A-Donor_03\|World / lung cells shred on cell class, cell subclass, sample id	A2M CYP26B1 ERG CCM2L	1.34e-04	187	62	4	fd93f3f4b82dae3bf4eef245bfedc2a9e3251b61
ToppCell	human_hepatoblastoma-NK.T_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	CRYBG1 SAMSN1 RUNX3 TRAV40	1.36e-04	188	62	4	71b7599e7e1d63cc0c8518c0501533755951d58f
ToppCell	PCW_05-06-Endothelial-Endothelial_immature-endo_immature4_(5)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	PITPNM2 CYP26B1 ERG CCM2L	1.36e-04	188	62	4	b9c5d573fc5ab0f7f38c55d006f9576634b05462
ToppCell	3'_v3-GI_small-bowel\|World / Manually curated celltypes from each tissue	SYTL2 REL SAMSN1 RUNX3	1.36e-04	188	62	4	822c6abaf7bcd6721269bdbd1f2b286ccf0aec1a
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	A2M ERG GLP1R NFASC	1.39e-04	189	62	4	7fbe855bfdb47d35e040b04a80fe4b729a3764e8
ToppCell	renal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	A2M ERG GLP1R NFASC	1.39e-04	189	62	4	06b35abecd29f902cf251fcc1f6ad33db7ab08a2
ToppCell	PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T\|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k)	A2M SYTL2 CRYBG1 RNF157	1.39e-04	189	62	4	5a9e2ca9a9ee2dc37ab9147a902115a9f1a80169
ToppCell	PND07-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-AEC-AEC_mature\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CYP26B1 ERG CCM2L RHPN2	1.39e-04	189	62	4	9da012fdfa9a8d488cab710a463a1d70e89f990c
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Descending_Vasa_Recta_Endothelial_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	A2M ERG CCM2L TTC28	1.39e-04	189	62	4	6463890d8dbee4bc198f91628a5f784970de786a
ToppCell	3'-GW_trimst-1-SmallIntestine-Endothelial-blood_vessel_EC-Mature_arterial_EC\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M CYP26B1 ERG CCM2L	1.39e-04	189	62	4	1d660bceee449aebf12fc9af4c74af246837b27a
ToppCell	Fetal_29-31_weeks-Immune-monocyte-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	CRYBG1 SAMSN1 RUNX3 MXD1	1.42e-04	190	62	4	ad297172a74a80ed5c10f921e15efd1da0fd2d6b
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c09-SLC4A10\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	A2M WHRN SYTL2 RUNX3	1.42e-04	190	62	4	05e6af222d0ad97cb69f399a96c9038f9dd989b9
ToppCell	3'-GW_trimst-1-LargeIntestine-Endothelial-blood_vessel_EC-Mature_arterial_EC\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	CYP26B1 CCM2L CRYBG1 SAMSN1	1.42e-04	190	62	4	92fdfed12061ee9f6c7171cf8a7f3344921f2d40
ToppCell	Control-T_cells-CD4+_T_cells\|Control / group, cell type (main and fine annotations)	PACS1 CRYBG1 SAMSN1 RUNX3	1.42e-04	190	62	4	0733be5e54fe15d6d6ea51c154a95258e83f1b92
ToppCell	5'-GW_trimst-1.5-SmallIntestine-Endothelial-blood_vessel_EC-cycling_EC\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	A2M CYP26B1 ERG CCM2L	1.42e-04	190	62	4	d4aefae2d3164db6a9e953c54af0151501e9d1da
ToppCell	Fetal_29-31_weeks-Mesenchymal-vascular_smooth_muscle_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	ERG GLP1R SYTL2 NFASC	1.42e-04	190	62	4	d6b3a92119b210974a32af3fe9875d60eb02761e
ToppCell	ILEUM\|World / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)	A2M CRYBG1 REL SAMSN1	1.42e-04	190	62	4	4395dbd18c14d491f5066a2ddac438a16b1fd7c3
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-DC-cDC2-G\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	CRYBG1 REL SAMSN1 MXD1	1.45e-04	191	62	4	7bad04f8afa949ea952c5c0d71eec43271ade680
ToppCell	PND07-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-AEC\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	CYP26B1 ERG CCM2L RHPN2	1.45e-04	191	62	4	3307dbccadb09c62b0e1c0235ec89bb294d748c3
ToppCell	343B-Endothelial_cells-Endothelial-B_(Artery)\|343B / Donor, Lineage, Cell class and subclass (all cells)	A2M CYP26B1 ERG TTC28	1.45e-04	191	62	4	27a532a35d9e8822014f581fd56c4ca62e39f8fe
ToppCell	Control-Lymphoid-T_Cytotoxic\|Control / Disease state, Lineage and Cell class	A2M SYTL2 CRYBG1 RUNX3	1.45e-04	191	62	4	03b5c5e0941c3402ab3f48cbf3da2a027d110421
ToppCell	Children_(3_yrs)-Immune-T_lymphocyte-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PACS1 SYTL2 SAMSN1 RUNX3	1.45e-04	191	62	4	c7be771543089fc94e5c62fd22f745189642aec3
ToppCell	343B-Endothelial_cells-Endothelial-B_(Artery)-\|343B / Donor, Lineage, Cell class and subclass (all cells)	A2M CYP26B1 ERG TTC28	1.45e-04	191	62	4	1dfcff08e01e6a695953334342bcfde04ba005ad
ToppCell	COVID-19-lung-CD4+_Treg\|lung / Disease (COVID-19 only), tissue and cell type	SYTL2 SAMSN1 RUNX3 RNF157	1.45e-04	191	62	4	73ea3078c1f55cd47e4d99e77b3ce4ff17549d49
ToppCell	COPD-Lymphoid-T_Cytotoxic\|World / Disease state, Lineage and Cell class	A2M SYTL2 CRYBG1 RUNX3	1.48e-04	192	62	4	5bfd9f5d47511441eb2d3cc3c4d7ed330ffd0bd1
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-T_cells-TRGV4_gdT\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	WHRN REL SAMSN1 RUNX3	1.48e-04	192	62	4	f4b5a55a648e366234079411b6fdd2da75a4740e
ToppCell	COVID-19-kidney-AQP1+PLVAP+EC\|COVID-19 / Disease (COVID-19 only), tissue and cell type	PITPNM2 MAGEB4 ERG TTC28	1.48e-04	192	62	4	27ff3621e177e7932dd44dd6baa81551ea75a874
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD8+_T-MAIT\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	A2M WHRN SYTL2 RUNX3	1.48e-04	192	62	4	892789bdba150ef9a8a0012de52545f2ff6a31f6
ToppCell	COVID-19_Mild-Lymphoid_T/NK-MAIT\|COVID-19_Mild / Disease group, lineage and cell class	A2M WHRN SYTL2 RUNX3	1.48e-04	192	62	4	d47bd132e57f5b4bddcf3dfa399cee149eca7e44
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD8+_T-MAIT-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	A2M WHRN SYTL2 RUNX3	1.48e-04	192	62	4	24ea8fdcca2695aeb2e4b88161184124b7d332c1
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD8+_T-MAIT-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	A2M WHRN SYTL2 RUNX3	1.48e-04	192	62	4	44f440ee3842fe14665c4cd4f2aa48e7a5bbd9a8
ToppCell	PBMC-Mild-Lymphocyte-T/NK-CD8+_T-MAIT\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	A2M WHRN SYTL2 RUNX3	1.48e-04	192	62	4	8d50ad8cfe3cb9f183188b08457756af0ce56ffe
ToppCell	renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Descending_Vasa_Recta_Endothelial_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	A2M ERG CCM2L TTC28	1.48e-04	192	62	4	56b021c297a21dff357531f21e2464f85186106d
Computational	Genes in the cancer module 539.	GYPA GYPB GYPE	2.21e-05	16	38	3	MODULE_539
Computational	Neighborhood of PCAF	GYPA GYPB GYPE	2.69e-04	36	38	3	GNF2_PCAF
Drug	Butylparaben [94-26-8]; Up 200; 20.6uM; MCF7; HT_HG-U133A	A2M KRT15 SLC34A1 GYPA NFASC PPIL2	1.20e-05	197	59	6	5245_UP
Drug	Streptozotocin [18883-66-4]; Up 200; 15uM; MCF7; HT_HG-U133A	WHRN GLP1R PPIL2 CYP4F12 MXD1 CCKAR	1.27e-05	199	59	6	6098_UP
Drug	TRITC	ERG GYPA GYPE	2.46e-05	22	59	3	CID000065134
Drug	Li Bo	GYPA GYPE	3.95e-05	4	59	2	CID006327674
Drug	Ddpc	GYPA GYPE	6.57e-05	5	59	2	CID000130969
Drug	5 alpha-ergostane	ERG REL	9.84e-05	6	59	2	CID000164641
Drug	Berol	GYPA GYPE	9.84e-05	6	59	2	CID000069182
Drug	Lithocholic acid [434-13-9]; Up 200; 10.6uM; HL60; HT_HG-U133A	PCLO PPIL2 SAMSN1 TEAD3 UBOX5	1.24e-04	187	59	5	2571_UP
Drug	Ethotoin [86-35-1]; Down 200; 19.6uM; PC3; HT_HG-U133A	PCLO SYTL2 REL MED1 UBOX5	1.27e-04	188	59	5	4545_DN
Drug	indomethacin, USP; Up 200; 20uM; MCF7; HG-U133A	A2M PACS1 PPIL2 EYA1 MED1	1.44e-04	193	59	5	262_UP
Drug	Decamethonium bromide [541-22-0]; Down 200; 9.6uM; MCF7; HT_HG-U133A	WHRN CYP26B1 GYPA GLP1R RUNX3	1.47e-04	194	59	5	4174_DN
Drug	Clenbuterol hydrochloride [21898-19-1]; Up 200; 12.8uM; MCF7; HT_HG-U133A	GYPB CYP4F12 UBOX5 OMG JPH3	1.51e-04	195	59	5	5631_UP
Drug	Brinzolamide [138890-62-7]; Down 200; 10.4uM; PC3; HT_HG-U133A	NUDT3 SYTL2 PPIL2 RUNX3 UBOX5	1.51e-04	195	59	5	6670_DN
Drug	S(+)-Terguride [37686-84-3]; Up 200; 11.8uM; HL60; HT_HG-U133A	SLC34A1 PCLO SYTL2 PPIL2 OMG	1.51e-04	195	59	5	3082_UP
Drug	Pirenzepine dihydrochloride [29868-97-1]; Down 200; 9.4uM; MCF7; HT_HG-U133A	PACS1 KRT15 TTC28 GLP1R PPIL2	1.51e-04	195	59	5	2234_DN
Drug	Chlorthalidone [77-36-1]; Down 200; 11.8uM; PC3; HT_HG-U133A	WHRN PACS1 RBM10 SYTL2 REL	1.51e-04	195	59	5	7152_DN
Drug	Hemicholinium bromide [312-45-8]; Down 200; 7uM; PC3; HT_HG-U133A	WHRN PACS1 GYPA PPIL2 CCKAR	1.51e-04	195	59	5	6739_DN
Drug	Cimetidine [51481-61-9]; Up 200; 15.8uM; PC3; HG-U133A	SLC34A1 PPIL2 UBOX5 MUC6 OMG	1.51e-04	195	59	5	1884_UP
Drug	Oxamniquine [21738-42-1]; Up 200; 14.4uM; MCF7; HT_HG-U133A	WHRN ERG GYPB CYP4F12 CCKAR	1.51e-04	195	59	5	4124_UP
Drug	(-)-Cinchonidine [485-71-2]; Down 200; 13.6uM; PC3; HT_HG-U133A	WHRN KRT15 RBM10 RUNX3 MAP3K7	1.54e-04	196	59	5	5833_DN
Drug	Fluoxetine hydrochloride [59333-67-4]; Up 200; 11.6uM; MCF7; HT_HG-U133A	WHRN PACS1 TRPA1 GLP1R PPIL2	1.54e-04	196	59	5	3314_UP
Drug	Enoxacin [74011-58-8]; Up 200; 12.4uM; MCF7; HT_HG-U133A	A2M TRPA1 GYPB GLP1R CYP4F12	1.54e-04	196	59	5	5251_UP
Drug	Sulfadiazine [68-35-9]; Up 200; 16uM; PC3; HT_HG-U133A	WHRN PACS1 PCLO SYTL2 UBOX5	1.54e-04	196	59	5	1810_UP
Drug	Raloxifene hydrochloride [82640-04-8]; Down 200; 7.8uM; PC3; HT_HG-U133A	GYPA GLP1R PCLO PPIL2 RUNX3	1.54e-04	196	59	5	5759_DN
Drug	GSK-3 Inhibitor IX; Down 200; 0.5uM; MCF7; HT_HG-U133A	WHRN SYTL2 ARFGEF1 PPIL2 MAP3K7	1.58e-04	197	59	5	7101_DN
Drug	Norgestrel-(-)-D [797-63-7]; Up 200; 12.8uM; MCF7; HT_HG-U133A	KRT15 GLP1R PCLO MUC6 CCKAR	1.58e-04	197	59	5	4730_UP
Drug	PNU-0293363 [326823-19-2]; Down 200; 10uM; MCF7; HT_HG-U133A	A2M PACS1 RBM10 MED1 UBOX5	1.58e-04	197	59	5	6573_DN
Drug	Benfotiamine [22457-89-2]; Up 200; 8.6uM; MCF7; HT_HG-U133A	WHRN GYPA PCLO CYP4F12 UBOX5	1.62e-04	198	59	5	3931_UP
Drug	iloprost; Down 200; 1uM; SKMEL5; HG-U133A	SLC29A3 CYP26B1 RBM10 UBOX5 OMG	1.62e-04	198	59	5	496_DN
Drug	Pheniramine maleate [132-20-7]; Up 200; 11.2uM; PC3; HG-U133A	TTC28 RBM10 CCDC25 PPIL2 TEAD3	1.62e-04	198	59	5	1910_UP
Drug	Tolfenamic acid [13710-19-5]; Up 200; 15.2uM; PC3; HT_HG-U133A	WHRN KRT15 PPIL2 RUNX3 UBOX5	1.62e-04	198	59	5	6354_UP
Drug	Iocetamic acid [16034-77-8]; Down 200; 6.6uM; MCF7; HT_HG-U133A	PACS1 PPIL2 CYP4F12 TEAD3 UBOX5	1.62e-04	198	59	5	3361_DN
Drug	Ketorolac tromethamine [74103-07-4]; Up 200; 10.6uM; MCF7; HT_HG-U133A	A2M WHRN GYPB MUC6 CCKAR	1.62e-04	198	59	5	5988_UP
Drug	Nilutamide [63612-50-0]; Up 200; 12.6uM; MCF7; HT_HG-U133A	WHRN KRT15 ERG GLP1R PPIL2	1.62e-04	198	59	5	6481_UP
Drug	Trimetazidine dihydrochloride [13171-25-0]; Up 200; 11.8uM; MCF7; HT_HG-U133A	WHRN KRT15 TTC28 PPIL2 RUNX3	1.62e-04	198	59	5	5479_UP
Drug	DO 897/99; Up 200; 8.2uM; MCF7; HT_HG-U133A	TTC28 GLP1R CCDC25 CYP4F12 UBOX5	1.62e-04	198	59	5	7462_UP
Drug	Tetramisole hydrochloride [16595-80-5]; Up 200; 16.6uM; MCF7; HT_HG-U133A	WHRN PACS1 GYPB PPIL2 RUNX3	1.62e-04	198	59	5	4412_UP
Drug	Iocetamic acid [16034-77-8]; Up 200; 6.6uM; MCF7; HT_HG-U133A	WHRN PACS1 KRT15 GYPB RUNX3	1.62e-04	198	59	5	4425_UP
Drug	Ritodrine hydrochloride [23239-51-2]; Up 200; 12.4uM; MCF7; HT_HG-U133A	WHRN GYPA GYPB UBOX5 CCKAR	1.66e-04	199	59	5	2635_UP
Drug	ICI182,780; Up 200; 1uM; PC3; HT_HG-U133A	KRT15 GYPA PPIL2 MED1 UBOX5	1.66e-04	199	59	5	7539_UP
Drug	Hydroquinine hydrobromide hydrate [304695-81-6]; Down 200; 9.4uM; PC3; HT_HG-U133A	PACS1 CYP26B1 PPIL2 RUNX3 UBOX5	1.66e-04	199	59	5	5789_DN
Drug	Tolbutamide [64-77-7]; Up 200; 14.8uM; MCF7; HT_HG-U133A	PACS1 CYP26B1 CYP4F12 RUNX3 MUC6	1.69e-04	200	59	5	3886_UP
Disease	diabetic neuropathy	GYPA GYPB GYPE	7.57e-08	5	59	3	EFO_1000783
Disease	protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2 measurement	A2M GYPB GYPE	1.51e-07	6	59	3	EFO_0801956
Disease	chronic bronchitis	GYPA GYPB GYPE	1.24e-06	11	59	3	EFO_0006505
Disease	cognitive behavioural therapy	ERG GYPA GYPB GYPE	5.64e-06	58	59	4	EFO_0007820
Disease	kidney volume	GYPA GYPB GYPE	6.07e-06	18	59	3	EFO_0600044
Disease	emphysema pattern measurement	GYPA GYPB GYPE	7.19e-06	19	59	3	EFO_0005850
Disease	cholangiocarcinoma (is_marker_for)	MUC16 RUNX3 MUC3A MUC6	8.37e-06	64	59	4	DOID:4947 (is_marker_for)
Disease	susceptibility to cold sores measurement	GYPA GYPB GYPE MUC16	8.91e-06	65	59	4	EFO_0008402
Disease	bipolar disorder, body mass index	GYPA GYPB GYPE JPH3	1.34e-05	72	59	4	EFO_0004340, MONDO_0004985
Disease	gas trapping measurement	GYPA GYPB GYPE	2.67e-05	29	59	3	EFO_0007628
Disease	resting heart rate, chronic obstructive pulmonary disease	GYPA GYPB GYPE	2.97e-05	30	59	3	EFO_0000341, EFO_0004351
Disease	blood pressure, chronic obstructive pulmonary disease	GYPA GYPB GYPE	3.61e-05	32	59	3	EFO_0000341, EFO_0004325
Disease	reticulocyte measurement	PITPNM2 PACS1 NUDT3 COPB1 GYPA GYPB GYPE EYA1 RUNX3 MXD1	4.12e-05	1053	59	10	EFO_0010700
Disease	pack-years measurement, systolic blood pressure	GYPA GYPB GYPE	4.35e-05	34	59	3	EFO_0006335, EFO_0006526
Disease	ornithine measurement	GYPA GYPB GYPE	9.49e-05	44	59	3	EFO_0009776
Disease	hip geometry	GYPA GYPB GYPE	9.49e-05	44	59	3	EFO_0004685
Disease	cryptic phenotype measurement	GYPA GYPB GYPE	1.16e-04	47	59	3	EFO_0021487
Disease	pulmonary function measurement, smoking behaviour measurement, FEV/FEC ratio	GYPA GYPB GYPE	1.16e-04	47	59	3	EFO_0003892, EFO_0004713, EFO_0005671
Disease	asthma	PITPNM2 SLC34A1 GYPA GYPB GYPE MUC16 MED1 RUNX3	1.20e-04	751	59	8	MONDO_0004979
Disease	unipolar depression, sex interaction measurement	GYPA GYPB GYPE	1.48e-04	51	59	3	EFO_0003761, EFO_0008343
Disease	essential tremor	GYPA GYPB GYPE NFASC	1.61e-04	136	59	4	EFO_0003108
Disease	pulmonary function measurement, FEV/FEC ratio	GYPA GYPB GYPE	1.66e-04	53	59	3	EFO_0003892, EFO_0004713
Disease	response to beta blocker, heart rate	GYPA GYPB GYPE	2.06e-04	57	59	3	EFO_0004326, EFO_0007766
Disease	reticulocyte count	PITPNM2 NUDT3 COPB1 GYPA GYPB GYPE EYA1 RUNX3 MXD1	2.17e-04	1045	59	9	EFO_0007986
Disease	cardiac troponin I change measurement	GYPB GYPE	3.02e-04	13	59	2	EFO_0600077
Disease	sexual dimorphism measurement	PITPNM2 PACS1 NUDT3 GYPA GYPB GYPE EYA1 TEAD3 OMG	3.29e-04	1106	59	9	EFO_0021796
Disease	–	GYPA GYPB	4.63e-04	16	59	2	611162
Disease	Malaria, susceptibility to	GYPA GYPB	4.63e-04	16	59	2	cv:C1970028
Disease	pulmonary function measurement	GYPA GYPB GYPE	5.00e-04	77	59	3	EFO_0003892
Disease	late-onset myasthenia gravis	EYA1 MAP3K7	5.89e-04	18	59	2	EFO_1001490
Disease	femoral neck bone mineral density	RHPN2 GYPA GYPB GYPE	6.46e-04	196	59	4	EFO_0007785
Disease	Malaria	GYPA GYPB	7.30e-04	20	59	2	C0024530
Disease	smoking status measurement, chronic obstructive pulmonary disease	GYPA GYPB GYPE	7.38e-04	88	59	3	EFO_0000341, EFO_0006527
Disease	total cortical area measurement	GYPA GYPB GYPE	8.94e-04	94	59	3	EFO_0008381
Disease	Eczema, allergic rhinitis	PITPNM2 REL RUNX3 MUC22	9.12e-04	215	59	4	EFO_0005854, HP_0000964
Disease	hearing impairment	WHRN SLC29A3 EYA1	1.01e-03	98	59	3	C1384666
Disease	malaria (is_implicated_in)	GYPA GYPB	1.05e-03	24	59	2	DOID:12365 (is_implicated_in)
Disease	pancreatic cancer (is_marker_for)	MUC16 MUC6 CCKAR	1.10e-03	101	59	3	DOID:1793 (is_marker_for)
Disease	cortical surface area measurement, neuroimaging measurement	GYPA GYPB GYPE MAP3K7	1.11e-03	227	59	4	EFO_0004346, EFO_0010736
Disease	chronic kidney disease (biomarker_via_orthology)	SLC34A1 MAP3K7	1.44e-03	28	59	2	DOID:784 (biomarker_via_orthology)
Disease	mean corpuscular hemoglobin concentration	CYP26B1 ERG TTC28 SLC34A1 GYPA GYPB GYPE SFXN2	1.54e-03	1105	59	8	EFO_0004528
Disease	neutrophil count	ERG TTC28 MYCBP2 GYPA GYPB GYPE SFXN2 RUNX3 MUC22	1.60e-03	1382	59	9	EFO_0004833
Disease	Ischemic stroke, von Willebrand factor measurement	KIRREL3 JPH3	1.65e-03	30	59	2	EFO_0004629, HP_0002140
Disease	Mental Depression	A2M SLC29A3 GYPE PCLO	1.68e-03	254	59	4	C0011570
Disease	erythrocyte measurement	GYPA GYPB GYPE LARP4	1.76e-03	257	59	4	EFO_0005047
Disease	forced expiratory volume, response to bronchodilator	CYP26B1 GYPA GYPB GYPE JPH3	1.96e-03	445	59	5	EFO_0004314, GO_0097366

Protein segments in the cluster

Peptide	Gene	Start	Entry
TSSSGIGSYSTQMSG	ARFGEF1	671	Q9Y6D6
TEMTASSSSDYGQTS	ERG	31	P11308
SDSSSTSMNVYSLSV	GSDMD	111	P57764
QGASLATSYSSTAMN	AMER1	1116	Q5JTC6
TTTYFMGTSVSVSTF	CCKAR	116	P32238
SMSSTSASAVRSYDG	CCM2L	506	Q9NUG4
SVSYTGSRSASNMAI	A2M	1366	P01023
SSQGTAANSQSYTIM	RBM10	516	P98175
YSTGKVSASFTSTAM	PPIL2	241	Q13356
YTMGETSVSISTSDF	MUC16	8386	Q8WXI7
MTVTTSGTSQSRSSF	MUC6	1726	Q6W4X9
GTTVGSMEEYNTSST	OR2T1	46	O43869
SMQSLGSDEGYSSTS	MXD1	191	Q05195
GTTAMTSAYSRATSS	MAGEB4	326	O15481
TSASTMASTAAFTTG	MUC22	76	E2RYF6
MASTAAFTTGSETNT	MUC22	81	E2RYF6
SSLSSGATAGSSMYT	GLP1R	441	P43220
AYSMSTGAVVTESQT	HERC2	2536	O95714
AAYATTASASTSLIM	CYP26B1	296	Q9NR63
YFTSAAMGTSTVEIT	ESF1	496	Q9H501
YSSYMTSSTSSIGGI	PCLO	4216	Q9Y6V0
VATTYSVSAQSSMSG	NUDT3	156	O95989
DSTTKIAYSTSMTGT	MUC3A	346	Q02505
IAYSTSMTGTLSTET	MUC3A	351	Q02505
DSTTRTTYSTNMTGT	MUC3A	1851	Q02505
TTYSTNMTGTLSTVT	MUC3A	1856	Q02505
TEMGTYATQSALSSS	COPB1	516	P53618
SYQMQGSSFTTSSGI	EYA1	181	Q99502
AMHTSTSSSVTKSYI	GYPE	26	P15421
NSATSTGSFMDIAST	MAP3K7	311	O43318
MTTTFLQTSSSTFGG	KRT15	1	P19012
ISIASQVSGMAESYT	PITPNM2	836	Q9BZ72
QVSGMAESYTASSIA	PITPNM2	841	Q9BZ72
TSSSVNSSAYTIYMG	CCDC25	6	Q86WR0
STSTSMAVAVASGSA	PACS1	71	Q6VY07
SMTFVVQSSSVFTSA	SLC34A1	411	Q06495
SSSMSSLTGAYASGI	POM121	391	Q96HA1
GISSTVITFMTSTAY	NFASC	1191	O94856
VSSGSYSYMTSSASE	FCSK	321	Q8N0W3
AMHTSTSSSVTKSYI	GYPB	26	P06028
NSTQMSATYSQGFTV	CYP4F12	76	Q9HCS2
AMHTSTSSSVTKSYI	GYPA	26	P02724
MYSSSCETTRNTTGI	LARP4	71	Q71RC2
TGMSFTNIYSTLSGQ	KIRREL3	671	Q8IZU9
SVTSVNTMTTAFSTS	CRYBG1	851	Q9Y4K1
MTASASSFSSSQGVQ	DUSP21	1	Q9H596
KLSSSMYSSQGSSGS	MED1	1126	Q15648
TTADGTSMQTSTYSE	MUC17	1556	Q685J3
TSSGSYQFSMVAGSS	RUNX3	336	Q13761
TSLSSVSGSVMSVYS	SYTL2	606	Q9HCH5
SGASTVFSSSIYGMT	SLC29A3	176	Q9BZD2
QNVTGLEMYTSASSS	UBOX5	76	O94941
QISTDTVSSMSGSYI	RNF157	526	Q96PX1
MALSYFTATTTAVAT	SFXN2	146	Q96NB2
GSTSSATNVTMVVSA	NBPF7P	11	P0C2Y1
MDSLYSGQSSSSGIT	SAMSN1	126	Q9NSI8
AVTAASSNTDMTYGG	MYCBP2	2336	O75592
TYSMVSYSDTGSSTG	WHRN	516	Q9P202
STSSMHNKSATYSVG	RHPN2	596	Q8IUC4
SGFTSSLFTVSGMQT	OMG	271	P23515
MISSYSGSVDIVNTT	TRPA1	291	O75762
GVSSQYSSADSMTIS	TEAD3	316	Q99594
YSSADSMTISVSTKV	TEAD3	321	Q99594
SDNQYLVMGSSSSAT	TLE7	421	A0A1W2PR48
SSSMSAGANSNTTVF	REL	541	Q04864
SVYSLSSIASSMSFV	TTC28	1991	Q96AY4
SEGASVTMNCTYTST	TRAV40	31	A0A0B4J280
QSSFRSEAGMSTVSS	JPH3	241	Q8WXH2